Deutsche Bank raises its target price on Buy-rated Regeneron Pharma REGN from $80 to $140 on Eylea WW increased sales projections.
Deutsche Bank says, "We modeled in close detail the refractory market highlighted in this note discussing how a robust refractory market could last for 1-2 years. We have increased our Eylea WW sales numbers and TP due to 1) Increased confidence in ex-US Eylea sales, 2) Eylea uptake in refractory AMD market and 3) Inclusion of BRVO numbers in the model. From Q4 call, 38% of Lucentis docs have now used Eylea after 12 weeks on market. Stocking looks low as docs keep 1 week and wholesalers keep 1-2 weeks of stock. Reimbursement is on track with all Medicare carriers and private payers."
REGN closed at $102.08 a share yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in